摘要
目的观察胰激肽原酶联合缬沙坦治疗早期糖尿病肾病(DN)患者血清胱抑素C(Cys C)及尿微量白蛋白排泄率(UAER)的变化。方法选择早期DN患者68例,随机分为观察组(36例)和对照组(32例)。对照组单独应用缬沙坦80 mg,每日1次,口服;观察组在对照组治疗的基础上加用胰激肽原酶针剂40 U,每日1次,肌肉注射。疗程均为4周。检测2组治疗前后Cys C及UAER的变化。结果 2组治疗后Cys C、UAER均较治疗前明显下降,差异具有统计学意义(P<0.05);观察组Cys C、UAER明显低于对照组(P<0.01)。结论胰激肽原酶联合缬沙坦治疗能更有效降低早期DN患者Cys C及UAER水平,可能对延缓早期DN的进展有一定作用。
Objective To investigate the variation of serum cystatin C （Cys C ） and urinary albumin excretion rate （UAER） in patients with early diabetic nephropathy（DN） after being treated with kallidinogenase combined with valsartan. Methods Sixty-eight patients with early DN were divided into treatment group （36 patients） and control group （32 patients） randomly. Patients in control group were given valsartan 80 mg orally, once a day. The treatment group was given valsartan 80 tng oraliy combined with kallidinogenase 40 U by intramscular injection, once a day. The course of treatment was 4 weeks. The changes of Cys C and UAER were detected before and after treatment. Results The Cys C and UAER in the two groups decreased significantly after treatment （P 〈 0.05 ）. The Cys C and UAER in the treatment group decreased much more than those of control group （P 〈 0.05）. Conclusion The levels of Cys C and UAER in patients with early DN can be obviously decreased and progression of early DN may be deferred by treating with kallidinogenase combined with valsartan.
出处
《新乡医学院学报》
CAS
2012年第8期594-596,共3页
Journal of Xinxiang Medical University
